Gyre Therapeutics, Inc. (GYRE)

Gyre Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022
Revenue	105.03	113.45	102.29
Revenue Growth (YoY)	-9.04%	10.91%	-
Cost of Revenue	3.96	4.64	4.79
Gross Profit	101.08	108.81	97.5
Selling, General & Admin	77.82	75.82	71.61
Research & Development	12.88	13.78	16.69
Operating Expenses	90.7	89.6	88.29
Operating Income	10.38	19.21	9.2
Interest & Investment Income	1.53	1.04	0.73
Earnings From Equity Investments	-0.17	-1.31	-0.25
Currency Exchange Gain (Loss)	-1.5	-1.5	-4.9
Other Non Operating Income (Expenses)	-3.08	-8.97	3.73
EBT Excluding Unusual Items	7.15	8.48	8.51
Gain (Loss) on Sale of Assets	-2.88	-3.34	-
Other Unusual Items	1	1	0.9
Pretax Income	-77.83	-76.97	9.41
Income Tax Expense	5.82	8.52	5.1
Earnings From Continuing Operations	-83.65	-85.48	4.31
Minority Interest in Earnings	-5.17	-7.45	-2.01
Net Income	-88.82	-92.93	2.3
Net Income to Common	-88.82	-92.93	2.3
Shares Outstanding (Basic)	82	66	64
Shares Outstanding (Diluted)	82	66	76
Shares Change (YoY)	28.56%	-13.02%	-
EPS (Basic)	-1.09	-1.41	0.04
EPS (Diluted)	-1.17	-1.41	0.03
Free Cash Flow	-2.23	17.38	5.69
Free Cash Flow Per Share	-0.03	0.26	0.08
Gross Margin	96.23%	95.91%	95.31%
Operating Margin	9.88%	16.94%	9.00%
Profit Margin	-84.57%	-81.92%	2.25%
Free Cash Flow Margin	-2.12%	15.32%	5.56%
EBITDA	11.8	20.33	10.33
EBITDA Margin	11.24%	17.92%	10.10%
D&A For EBITDA	1.43	1.11	1.13
EBIT	10.38	19.21	9.2
EBIT Margin	9.88%	16.94%	9.00%
Effective Tax Rate	-	-	54.16%

Source: S&P Capital IQ. Standard template. Financial Sources.